Sat 24 Oct 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of KB195 in Subjects with a Urea Cycle Disorder with Inadequate Control on Standard of Care | Kaleido Biosciences | Completed | KB195 | 2 | K020-218 | KKUH |
| A Phase 1/2 Open-label Clinical Study of hLB-001 Gene Therapy in Pediatric Patients With Methylmalonic Acidemia Characterized by MMUT Mutations | Logic Bio Therapeutics | Ongoing | AAV-hHA-hMUT | 1 | LB001-001 | King Abdulaziz Medical City NG (Riyadh) |
| A PARTIALLY DOUBLE-BLINDED, RANDOMIZED, CONTROLLED, PLACEBO-CONTROLLED STUDY, A PHASE III TRIAL OF SAFETY AND EFFICACY OF PREMEDICATION WITH DEXMEDETOMIDINE AND MIDAZOLAM IN PEDIATRIC PATIENTS | King Faisal Specialist Hospital and Research Centre | Ongoing | DEXMEDETOMIDINE | 3 | RAC# 21901310 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| "A Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients with Sickle Cell Disease and Other Hemoglobinopathies " | KAIMRC | Ongoing | HYDROXYUREA (HYDROXYCARBAMIDE) | 3 | CT20/008/R | King Abdulaziz Medical City NG (Riyadh) |
| A National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19 | GDRS (MOH) | Ongoing | Convalescent Plasma | 2 | 20-COVID-19-01M | KFSH-D |
| A multinational, open-label, randomised, controlled trial to investigate efficacy and safety of NNC0365-3769 (Mim8) in adults and adolescents with haemophilia A with or without inhibitors. | Novo Nordisk | Ongoing | Mim8 | 3 | NN7769-4514 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| "A Multinational, Open Label, Randomized, Active-controlled, 3-arm Parallel Group, 24-week Study Comparing the Combination of Glimepiride and Metformin Versus Glimepiride and Metformin Alone in Patients With Type 2 Diabetes " | Sanofi | Terminated | GLIMEPIRIDE-HOE490 | 3 | GLIME_R_05809 | KFSH |
| A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma (NAVIGATOR) | AstraZeneca | Completed | Tezepelumab | 3 | D5180C00007 | KAUH-J |
| A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma (DESTINATION) | AstraZeneca | Ongoing | Tezepelumab | 3 | D5180C00018 | KAUH-J |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome | Takeda | Rejected | Alogliptin | 3 | SYR-322_402 | PSMMC |
Last update date: 06/10/2026 at 08:14 AM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.